Views & Analysis Searching for new hope in Alzheimer’s For the best part of two decades, it seemed as if pharma hit a brick wall as it tried to find new treatments for Alzheimer’s.
R&D Citing phase 2 figures, Axon looks for big pharma investment... After trial failure upon trial failure in Alzheimer's disease will big pharma be prepared to fund a trial using a new approach instead of the amyloid-targeting drugs, that have caused so mu
News GSK pursues $10.6bn takeover of cancer biotech Nuvalent GSK is preparing for its biggest acquisition in more than 10 years, agreeing to buy cancer drug developer Nuvalent for $10.6 billion.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
